The Minnesota Department of Health announced Monday that it was adding the degenerative neurological disorder to the program, despite limited evidence on the effectiveness of treatment with cannabis. Some studies have found that marijuana inhibits the formation of tau proteins that accelerate dementia and memory loss related to the disease.
“Any policy decisions about cannabis are difficult due to the relative lack of published scientific evidence,” said state Health Commissioner Jan Malcolm. “However, there is some evidence for potential benefits of medical cannabis to improve the mood, sleep and behavior of patients suffering from Alzheimer’s disease.”
Malcolm declined to add six other conditions that had been submitted this summer to a state advisory panel. The others were hepatitis C, juvenile rheumatoid arthritis, opioid use disorders, panic disorder, psoriasis and traumatic brain injury.
Read the full story at the Star Tribune.